UBS Group Initiates Coverage on Zoetis (NYSE:ZTS)

UBS Group assumed coverage on shares of Zoetis (NYSE:ZTS) in a report issued on Monday,Benzinga reports. The firm set a “neutral” rating and a $196.00 price target on the stock. UBS Group’s price target would indicate a potential upside of 10.92% from the company’s previous close.

Several other analysts have also commented on the stock. BTIG Research raised their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Stifel Nicolaus raised their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Leerink Partners started coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Piper Sandler raised their price target on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Zoetis presently has an average rating of “Buy” and a consensus target price of $216.70.

Zoetis Stock Down 0.8 %

NYSE:ZTS opened at $176.71 on Monday. The firm has a market capitalization of $79.73 billion, a P/E ratio of 33.22, a PEG ratio of 2.88 and a beta of 0.89. Zoetis has a 1-year low of $144.80 and a 1-year high of $201.92. The company’s fifty day moving average price is $181.72 and its 200-day moving average price is $181.12. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.36 earnings per share. As a group, equities research analysts anticipate that Zoetis will post 5.9 EPS for the current year.

Institutional Trading of Zoetis

Several institutional investors have recently modified their holdings of ZTS. Simplify Asset Management Inc. purchased a new position in shares of Zoetis in the third quarter worth about $11,684,000. B&L Asset Management LLC purchased a new position in shares of Zoetis in the third quarter worth about $563,000. Swedbank AB lifted its stake in shares of Zoetis by 56.2% in the second quarter. Swedbank AB now owns 1,946,277 shares of the company’s stock worth $337,407,000 after buying an additional 700,398 shares in the last quarter. Dai ichi Life Insurance Company Ltd lifted its stake in shares of Zoetis by 16.3% in the third quarter. Dai ichi Life Insurance Company Ltd now owns 74,499 shares of the company’s stock worth $14,556,000 after buying an additional 10,427 shares in the last quarter. Finally, Raymond James & Associates lifted its stake in shares of Zoetis by 6.1% in the second quarter. Raymond James & Associates now owns 794,419 shares of the company’s stock worth $137,720,000 after buying an additional 45,597 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.